Backbone Modified Peptide-nucleic Acids as Antiviral Agents Against Hepatitis C
Backbone Modified Peptide-nucleic Acids as Antiviral Agents Against Hepatitis C
批准号:
8253898
负责人:
MIHAELA R MIHAILESCU
金额:
$6.2万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-02-15 至 2013-02-14
关键词:
3&apos Untranslated Regions5&apos Untranslated RegionsAffectiveAffinityAntiviral AgentsBase PairingBindingBiologicalCellsChildCircular Dichroism SpectroscopyCodeCollaborationsCombined Modality TherapyComplementary DNAComplementary RNAComplexConserved SequenceCore ProteinDNADataDevelopmentFamilyFlaviviridaeFutureGeneticGenetic TranscriptionGenomeGenomicsGenotypeGlycineGlycoproteinsGoalsHealthHepatitis CHepatitis C virusIncidenceLaboratoriesLife Cycle StagesLipidsLiver CirrhosisMethodsModificationMolecularNMR SpectroscopyNorth CarolinaNucleic AcidsNucleocapsidOpen Reading FramesPatientsPeptide HydrolasesPeptide Nucleic AcidsPharmaceutical PreparationsPlayPrimary carcinoma of the liver cellsRNARNA-Directed RNA PolymeraseRecombinant Interferon AlfaResearchResearch PersonnelRibavirinRoleSeriesSpecificitySugar PhosphatesTestingTherapeuticTrainingTranslationsUniversitiesVertebral columnViralViral ProteinsVirionVirusVirus Replicationanalogbiophysical chemistrycareerdesigngel electrophoresisin vivoinhibitor/antagonistmembermiddle agenovel therapeuticsnucleasenucleic acid inhibitorviral RNAyoung woman
中文摘要
描述(由申请人提供):随着超过2亿人感染,丙型肝炎病毒(HCV)在全球范围内构成了一个主要的健康问题。目前使用重组α干扰素和利巴韦林治疗HCV感染的疗法仅在少于50%的患者中有效,并且慢性HCV感染的患者可发展严重的健康问题,包括肝硬化和肝细胞癌。因此,迫切需要开发新的治疗策略。HCV的基因组由正链RNA编码,其包含侧接5 '和3'非翻译区(UTR)的开放阅读框。尽管病毒的突变率很高,但HCV RNA编码区及其5 '-和3'-UTR含有进化上保守的序列,这些序列被认为参与了一系列复杂的相互作用。虽然这些相互作用的分子机制还不完全清楚,但遗传数据表明它们在病毒复制和翻译中起着重要作用。因此,考虑到它们在HCV生命周期中的重要作用,抑制这些涉及所有HCV基因型中100%保守区域的相互作用是一种有吸引力的抗病毒策略,并且这是本发明的长期目标。
该项目有以下具体目标:具体目标1。设计和合成靶向病毒复制和翻译所必需的HCV基因组RNA的保守区域的肽-核酸。具体目标2。分析设计的PNA破坏HCV RNA基因组内高度保守区域之间的长程相互作用,抑制HCV复制和翻译的能力。
公共卫生相关性:所提出的研究的意义是显而易见的,因为肽核酸(PNA)抑制剂建议在这些研究中合成和分析,HCV基因组内100%保护的目标区域。这些?修饰的PNA旨在破坏这些区域之间基本的长程相互作用,这种相互作用对于病毒生命周期的生物学意义已经由遗传数据确定。因此,这些研究有可能确定HCV复制和翻译的有效抑制剂,考虑到HCV感染在世界范围内造成的主要健康问题,其发病率超过2亿人,这是一项迫切的任务。
英文摘要
DESCRIPTION (provided by applicant): With more than 200 million people infected, the Hepatitis C virus (HCV) poses a major health problem worldwide. The current therapy to treat HCV infections, which uses recombinant alpha interferon and ribavirin, is efficient only in less than 50% of the patients and chronically HCV infected patients can develop serious health problems which include liver cirrhosis and hepatocellular carcinoma. Thus, there is an urgent need for the development of new therapeutic strategies. HCV has its genome encoded by a positive-strand RNA, which contains an open reading frame flanked by 5'- and 3'-untranslated regions (UTRs). Despite the high mutational rate of the virus, the HCV RNA coding region, as well as its 5'- and 3'-UTRs contain evolutionary conserved sequences proposed to be involved in an intricate array of long-range interactions with each other. Although the molecular mechanisms of these interactions are not all clear, genetic data indicates that they play vital roles in the virus replication and translation. Thus, the inhibition of these interactions which involve regions of 100% conservancy among all HCV genotypes, is an attractive antiviral strategy, given their essential roles in the HCV life cycle, and this is the long term goal of this
project, which has the following specific aims: Specific aim 1. Design and synthesis of peptide-nucleic acids which target conserved regions of the HCV genomic RNA essential for the viral replication and translation. Specific aim 2. Analyze the ability of the designed PNAs to disrupt the long-range interactions between regions of highly conservancy within the HCV RNA genome, inhibiting HCV replication and translation.
PUBLIC HEALTH RELEVANCE: The significance of the proposed research is evident, as the peptide nucleic acid (PNA) inhibitors proposed to be synthesized and analyzed in these studies, target regions of 100% conservancy within the HCV genome. These ?-modified PNAs aim to disrupt essential long- range interactions between these regions, interactions whose biological significance for the viral life cycle has been established by genetic data. Thus, these studies have the potential to identify efficient inhibitors for HCV replication and translation, an imperatve task, considering the major health problem posed worldwide by the HCV infection, whose incidence is over 200 million people.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Functional studies of the Fragile X Mental Retardation Protein: switching from re
-
批准号:7934339
-
项目类别:
-
资助金额:$12.4万
-
财政年份:2009
-
负责人:MIHAELA R MIHAILESCU
-
依托单位:
G quartet RNA-FMRP interactions in Fragile X syndrome
-
批准号:6954409
-
项目类别:
-
资助金额:$21.01万
-
财政年份:2005
-
负责人:MIHAELA R MIHAILESCU
-
依托单位:
Fragile X Mental Retardation Protein translation regulator function: interactions
-
批准号:8494883
-
项目类别:
-
资助金额:$39.42万
-
财政年份:2005
-
负责人:MIHAELA R MIHAILESCU
-
依托单位:
Biochemical characterization of a novel Fragile X Mental Retardation Protein nuclease function
-
批准号:10359289
-
项目类别:
-
资助金额:$41.4万
-
财政年份:2005
-
负责人:MIHAELA R MIHAILESCU
-
依托单位:
Investigation of Fragile X mental retardation protein interactions with the miRNA pathway.
-
批准号:9303733
-
项目类别:
-
资助金额:$41.4万
-
财政年份:2005
-
负责人:MIHAELA R MIHAILESCU
-
依托单位:
Biochemical characterization of a novel Fragile X Mental Retardation Protein nuclease function
-
批准号:10793981
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2005
-
负责人:MIHAELA R MIHAILESCU
-
依托单位:
海外基金